Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

Chii-Shyan Wang; Hsuan-Hsiang Chen; Shih-Hao Liu

doi:10.1016/j.jfma.2021.12.028

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

J Formos Med Assoc. 2022 May;121(5):1003-1007. doi: 10.1016/j.jfma.2021.12.028. Epub 2022 Jan 5.

Authors

Chii-Shyan Wang¹, Hsuan-Hsiang Chen², Shih-Hao Liu³

Affiliations

¹ Department of Dermatology, En Chu Kong Hospital, New Taipei City, Taiwan.
² Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: beauty101@gmail.com.
³ Department of Pathology, En Chu Kong Hospital, New Taipei City, Taiwan.

Abstract

Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. During this pandemic, acute COVID-19 infection has been related to PR or PR-like eruptions in several cases. Various COVID-19 vaccines associated with PR-like eruptions were rarely reported. Herein, we report a case of cutaneous PR-like eruptions following COVID-19 mRNA-1273 vaccination.

Keywords: COVID-19; Pityriasis rosea; mRNA vaccine.

Publication types

Case Reports
Review

MeSH terms

2019-nCoV Vaccine mRNA-1273
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Exanthema*
Herpesvirus 6, Human*
Humans
Pityriasis Rosea* / etiology
Vaccination / adverse effects

Substances

COVID-19 Vaccines
2019-nCoV Vaccine mRNA-1273